KRAS and non-small cell lung carcinoma: Our group and others have shown that SHP2 blockade in combination with MEK inhibitors could be beneficial for patients harboring KRAS mutant pancreatic [19], non‐small‐cell lung cancer (NSCLC) [20], serous ovarian and triple negative breast cancer (TNBC) [21] tumors as well as KRAS WT‐amplified gastroesophageal tumors [22].